US-based privately held medical device company Diality, which is developing a portable haemodialysis system, has closed a $12.5m Series B investment round.
The funding will support the company’s effort in the development of its portable system for acute and chronic haemodialysis.
The system is being developed to deliver intense dialysis doses commonly prescribed for patients, receiving three dialysis treatments per week and lower-intensity doses required for more frequent dialysis.
Furthermore, Diality’s system is expected to reduce the burden of care for kidney patients and improve their quality of life while providing physicians with the flexibility to prescribe personalised dialysis treatments regardless of delivery setting.
Diality CEO Osman Khawar said: “Driven by rising costs and poor outcomes associated with in-centre dialysis, as well as the Covid-19 impact on the industry, dialysis delivery is becoming decentralised. To accommodate cost-effective delivery outside of speciality dialysis facilities, haemodialysis machines need to be user-friendly for non-speciality nurses, patients, and care partners.
“To meet the needs of prescribing physicians and their patients in acute, sub-acute and home settings, a portable machine also needs to be capable of delivering a wide range of dialysis doses.
“The timing of this round positions us to leverage growing interest in this relatively new category of hemodialysis product where we see an opportunity for innovation that better addresses the distinct needs of dialysis providers across all segments of the market.”
Diality is currently focusing on obtaining 510(k) clearance from the Food and Drug Administration (FDA) for its haemodialysis system.